Curio

What Curio does

Curio Digital Therapeutics Inc. is a Princeton, New Jersey-based private digital therapeutics company that builds an AI-enabled, digital-first behavioral health platform for women's mental health across the full life-stage continuum: fertility (FertiLift), pregnancy and postpartum (MamaLift, including the FDA-cleared MamaLift Plus Prescription Digital Therapeutic), and menopause (MenoLift). The platform delivers evidence-based cognitive behavioral therapy and interpersonal therapy interventions in a gamified mobile app format, augmented by an AI virtual navigator chatbot, mood/sleep/activity trackers, augmented reality features, and access to live health coaches and therapists. Layered on top is Curio-i, a proprietary AI-driven predictive analytics platform that claims to identify 88% of women by the beginning of their third trimester who will go on to develop postpartum depression, with clinician-facing reporting dashboards. The company has built what it describes as the largest body of clinical evidence in women's digital health, with 7 published studies including randomized controlled trials covering over 2,500 women.

The company pursues a multi-channel go-to-market combining direct-to-consumer distribution via the Apple App Store and Google Play (with payment processing through Square), enterprise B2B SaaS contracts with health plans, self-insured employers, and health systems (with a stated 5:1 return-on-investment pitch), prescription reimbursement for MamaLift Plus, and a franchise-based in-person clinic model acquired in May 2026 via Nora Mental Health (24 locations across 16 US states). Named enterprise partners and customers include Metro Nashville Public Schools, Mount Sinai, Columbia University, and Prange Pharma. Revenue mechanics are not publicly disclosed at the price-point level, but pricing is quote-based for B2B contracts and subscription/transaction-based for the consumer app and PDT. The company is venture-backed with approximately $8 million in disclosed seed funding and several subsequent non-dilutive and dilutive financing engagements, and employs between 11 and 50 people.

Name

Curio

Legal name

Curio Digital Therapeutics Inc.

Website

https://curiodigitaltx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Curio Digital Therapeutics is a private digital therapeutics company that delivers an AI-enabled behavioral health platform for women across fertility, pregnancy, postpartum, and menopause life stages, including the first FDA-cleared prescription digital therapeutic for postpartum depression. The company serves consumers via mobile apps, health plans and self-insured employers via enterprise contracts, and now operates in-person clinics via its 2026 Nora Mental Health acquisition.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Women's Mental Health

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Residential Mental Health and Substance Abuse Facilities (623220)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

akta.pro secondary industries

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Maternal Mental Health Telehealth (perinatal anxiety/depression, support programs) (HLALAHAH)

Keywords

• Digital therapeutics
• Women's mental health
• Behavioral health platform
• Prescription digital therapeutic
• Predictive analytics healthcare

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. B2B Enterprise Subscription (Health Plans & Employers): Recurring SaaS-style contracts sold to health plans, self-insured employers (e.g., Metro Nashville Public Schools), and health systems. Pitches a 5:1 return on investment. Recurring revenue based on covered member populations and member engagement.
2. Consumer BellaLift App Purchases: Direct-to-consumer BellaLift / Curio App distributed via the Apple App Store and Google Play. Payment processing handled by Square, indicating consumer paid downloads or in-app subscription purchases.
3. Prescription Digital Therapeutic (PDT) Reimbursement: Revenue from MamaLift Plus, the first FDA-authorized prescription digital therapeutic for postpartum depression, fulfilled via healthcare provider prescription and reimbursed through standard payer pathways.
4. Franchise & In-Person Outpatient Therapy (Nora Mental Health): Acquired in 2026: Nora Mental Health, an outpatient therapy franchisor with 24 franchise locations across 16 US states. Curio plans to expand franchise footprint and provide franchisees with marketing, payer relationships, and clinical resources, generating revenue via franchise fees and in-person therapy services.

Pricing tiers

Go-to-market motion5 records

Distribution channels5 records

Marketing channels6 records

Core offering

Curio develops and sells digital therapeutics for women's mental health through its BellaLift platform, which delivers stage-based programs (FertiLift for fertility, MamaLift for pregnancy/postpartum, MenoLift for menopause) combining AI-driven personalization, cognitive behavioral therapy lessons, health trackers, and access to live health coaches. The company also offers Curio-i, an AI-powered predictive analytics platform that identifies women at risk of postpartum depression, and MamaLift Plus, the first FDA-authorized prescription digital therapeutic for postpartum depression.

Product overview

Curio offers a single unified digital therapeutics platform called BellaLift, organized as a platform-plus-modules architecture that is delivered through the Curio App. The BellaLift core platform hosts a set of stage-based sub-programs tailored to women's mental well-being: FertiLift (fertility), MamaLift (pregnancy and postpartum), MamaLift Plus (the FDA-cleared Prescription Digital Therapeutic for postpartum depression), and MenoLift (perimenopause and menopause). Layered on top is Curio-i, a separate AI-driven predictive analytics platform that identifies women at risk of postpartum depression and provides clinician-facing dashboards. Together, the BellaLift programs, the Curio App client, and Curio-i form Curio's full product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• BellaLift: Digital healthcare platform for women's mental well-being; umbrella platform comprising FertiLift, MamaLift, and MenoLift programs.
• Curio-i
• MamaLift Plus

Products and services

• BellaLift
• MamaLift
• MamaLift Plus
• FertiLift
• MenoLift
• Curio-i

Quantifiable outcome

• 86% experience clinically meaningful reduction of symptoms
• +9 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability12 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered flagship, major, minor and operational.

• Nora Mental HealthflagshipStrategic or Co-development Partner · 1 May 2026Acquired in 2026: Nora Mental Health is an outpatient therapy franchisor that operates 24 franchise locations across 16 US states. The acquisition combines Curio's telehealth and digital tools focused on women's health with Nora's in-person clinic model. Curio plans to expand the Nora franchise footprint while providing franchisees with additional support, marketing, payer relationships, and clinical resources. Terms were undisclosed.
• Mount SinaimajorStrategic or Co-development PartnerMount Sinai is listed as an early adopter and partner of Curio on the company website. As a leading academic medical center, the partnership supports clinical research, integration of Curio's digital therapeutics into clinical care, and validation of Curio's evidence-based approach to women's mental health.
• Columbia UniversitymajorStrategic or Co-development PartnerColumbia University is listed as an early adopter and partner of Curio. The academic partnership likely supports research collaboration, clinical validation, and access to scientific expertise in women's health and mental health.
• Metro Nashville Public Schools (MNPS)majorChannel Partner/ Reseller/ DistributorMetro Nashville Public Schools is listed as an early adopter and partner of Curio, indicating that MNPS provides Curio's digital behavioral health platform access to its workforce, likely as part of its employee benefits program for a workforce with many women of reproductive age.
• Prange PharmaminorGTM or Marketing PartnerPrange Pharma is listed as an early adopter and partner of Curio. As a pharmaceutical company, the partnership likely supports distribution, awareness, or complementary offering of Curio's digital therapeutics alongside pharmaceutical interventions.
• SquareoperationalTechnology or IntegrationSquare is Curio's third-party payment processor. When users provide payment information through the Curio App, payment processing is offered through Square, which collects, uses, and processes payment information in accordance with its privacy policies. Square shares completed transaction information with Curio for order fulfillment.
• Google (Google Analytics, Health Connect)operationalTechnology or IntegrationGoogle provides analytics and data collection tools (Google Analytics) to track visitor behavior on the Curio Application. Curio also integrates with Health Connect on Android to collect health-related data, adhering to Health Connect's Limited Use requirements.
• Meta (Facebook)operationalTechnology or IntegrationCurio uses Meta Pixel to track non-personal information relating to visitors who navigated to the Application from a Facebook ad, enabling advertising attribution and retargeting campaigns.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Maven Clinic: Maven Clinic is a digital women's and family health platform covering fertility, pregnancy, postpartum, and menopause with virtual care and employer/payer contracts. It is the closest direct competitor to Curio's end-to-end BellaLift platform and shares the same B2B employer/health plan and D2C GTM.
• Ovia Health (Labcorp): Ovia Health, acquired by Labcorp, offers digital health programs for fertility, pregnancy, and postpartum with employer/payer distribution. It directly competes with Curio's MamaLift and FertiLift modules and shares the women's mental and reproductive health vertical focus.
• Babyscripts: Babyscripts is a digital maternal health platform with remote monitoring, mental health screening, and payer/employer distribution. It overlaps with Curio's MamaLift pregnancy and postpartum offering and pursues the same health-plan value-based-care contracts.
• Woebot Health: Woebot Health is an AI-driven digital therapeutic company for mental health, combining AI chatbot delivery with clinical evidence. It competes with Curio on AI-enabled behavioral health delivery and on building evidence-based digital therapeutics.
• Big Health: Big Health develops FDA-cleared digital therapeutics (Sleepio, Daylight) for insomnia and anxiety distributed via employers and payers. It is a direct peer as a digital therapeutics company with FDA clearance, employer/payer GTM, and behavioral health focus.
• Akili Interactive: Akili Interactive is a publicly listed (formerly) prescription digital therapeutics company with FDA-cleared EndeavorRx. It is a direct peer in the FDA-cleared PDT category and shares the challenge of scaling reimbursement for novel digital therapeutics.
• Lyra Health: Lyra Health is a mental health benefits platform for employers and health plans combining virtual therapy, coaching, and self-guided digital programs. It competes with Curio for the same employer and payer contracts in mental health.

Broad incumbents

• Headspace Health: Headspace Health (Headspace + Ginger) is a large digital mental health platform with employer/payer distribution and self-guided digital programs. It is a broad incumbent offering overlapping capabilities across the mental health continuum where Curio also sells.
• BetterHelp (Teladoc Health): BetterHelp, owned by Teladoc Health, is the largest direct-to-consumer online therapy platform. It is a broad incumbent in digital mental health and competes for consumer mindshare and enterprise referrals adjacent to Curio's offering.

Emerging players

• Progyny: Progyny is a fertility benefits management platform sold to employers and health plans. It is an emerging player that overlaps with Curio's FertiLift module and competes for the same employer/payer women's health budget.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/curiodtx
• LinkedInlinkedin.com/company/curio-digital-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curio